NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00824785,REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer,https://clinicaltrials.gov/study/NCT00824785,REAL3,TERMINATED,"To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients with advanced stomach and oesophageal cancer.",NO,Oesophago-gastric Cancer,"DRUG: epirubicin, oxaliplatin, capecitabine (EOX)|DRUG: EOX + panitumumab","Overall survival, Study closed early due to lack of efficacy, Early termination","response rate, toxicity, quality of life and PFS, Study closed early due to lack of efficacy, Early termination",,Royal Marsden NHS Foundation Trust,,ALL,"ADULT, OLDER_ADULT",PHASE3,574,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CCR3024,2008-05,2013-02,2013-02,2009-01-19,,2012-12-11,"Bournemouth, Bournemouth, United Kingdom|St Luke's Guildford, Guildford, United Kingdom|Royal Liverpool, Liverpool, United Kingdom|Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom|Newcastle, Newcastle, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, United Kingdom|Clatterbridge Oncology Centre, Wirral, United Kingdom",
